Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients

The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid...

Full description

Saved in:
Bibliographic Details
Main Authors: Marina Alexandre, Gérôme Bohelay, Thomas Gille, Christelle Le Roux-Villet, Isaac Soued, Florence Morin, Frédéric Caux, Sabine Grootenboer-Mignot, Catherine Prost-Squarcioni
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Immunology
Subjects:
omalizumab (Xolair)
mucous membrane pemphigoid (MMP)
bullous pemphigoid (BP)
autoimmune bullous diseases (AIBDs)
autoimmune skin diseases
Immunoglobulin E (IgE)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.874108/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items